INBX

Inhibrx, Inc.

36.85 USD
-0.15 (-0.41%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Inhibrx, Inc. stock is down -4.9% since 30 days ago. The next earnings date is May 6, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 3 February’s closed higher than January. In the last 8 Unusual Options Trades, there were 7 CALLs, 1 PUT.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
29 Dec 16:51 19 Jan, 2024 40.00 CALL 68 252
29 Dec 16:51 19 Jan, 2024 40.00 CALL 43 252
29 Dec 16:53 19 Jan, 2024 40.00 CALL 53 252
29 Dec 18:14 19 Jan, 2024 35.00 CALL 84 626
29 Dec 18:25 19 Jan, 2024 35.00 CALL 100 626
29 Dec 18:27 19 Jan, 2024 40.00 CALL 99 252
29 Dec 18:52 19 Jan, 2024 35.00 CALL 50 626
23 Jan 15:04 16 Feb, 2024 35.00 PUT 2825 2

About Inhibrx, Inc.

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma.